Evidence map›Paper›PMID 35075768›Full record

ArticleJournal of cellular and molecular medicine2022

Enhanced effect of recombinant adenoviruses co-expression of ING4 and OSM on anti-tumour activity of laryngeal cancer.

Fuwei Cheng, Shuangping Zhao, Jiachen Li, Yuyu Niu, Haiping Huang, Jicheng Yang, Shiyin Ma, Jisheng Liu, Peng Sun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Translational cancer research · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Fuwei ChengDepartment of Otolaryngology, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID 0000-0002-1998-3348
Shuangping ZhaoDepartment of Otolaryngology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jiachen LiDepartment of Otolaryngology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yuyu NiuDepartment of Otolaryngology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Haiping HuangDepartment of Otolaryngology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jicheng YangCell and Molecular Biology Institute, College of Medicine, Soochow University, Suzhou, China.
Shiyin MaDepartment of Otolaryngology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Jisheng LiuDepartment of Otolaryngology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Peng SunDepartment of Otolaryngology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Soochow University · CNBengbu Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inhibitor of growth family member 4 (ING4) is one of the ING family genes, serves as a repressor of angiogenesis or tumour growth and suppresses loss of contact inhibition. Oncostatin M (OSM) is a multifunctional cytokine that belongs to the interleukin (IL)-6 subfamily with several biological activities. However, the role of recombinant adenoviruses co-expressing ING4 and OSM (Ad-ING4-OSM) in anti-tumour activity of laryngeal cancer has not yet been identified. Recombinant Ad-ING4-OSM was used to evaluate their combined effect on enhanced anti-tumour activity in Hep-2 cells of laryngeal cancer in vivo. Moreover, in vitro function assays of co-expression of Ad-ING4-OSM were performed to explore impact of co-expression of Ad-ING4-OSM on biological phenotype of laryngeal cancer cell line, that is Hep-2 cells. In vitro, Ad-ING4-OSM significantly inhibited the growth, enhanced apoptosis, altered cell cycle with G1 and G2/M phase arrest, and upregulated the expression of P21, P27, P53 and downregulated survivin in laryngeal cancer Hep-2 cells. Furthermore, in vivo functional experiments of co-expressing of Ad-ING4-OSM demonstrated that solid tumours in the nude mouse model were significantly suppressed, and the co-expressing Ad-ING4-OSM showed a significant upregulation expression of P21, P53, Bax and Caspase-3 and a downregulation of Cox-2, Bcl-2 and CD34. This study for the first time demonstrated the clinical value and the role of co-expressing Ad-ING4-OSM in biological function of laryngeal cancer. This work suggested that co-expressing Ad-ING4-OSM might serve as a potential therapeutic target for laryngeal cancer patients.

Indexed as

AdenoviridaeLaryngeal NeoplasmsAnimalsApoptosisCarrier ProteinsCell Cycle ProteinsCell Line, TumorGenetic TherapyHomeodomain ProteinsHumansMiceOncostatin MTumor Suppressor Protein p53Tumor Suppressor ProteinsCarrier ProteinsCell Cycle ProteinsHomeodomain ProteinsING4 protein, humanING4 protein, mouseOncostatin MOSM protein, humanTumor Suppressor Protein p53Tumor Suppressor Proteinsgene therapygrowth family member 4laryngeal cancerOncostatin M

Identifiers

PMID35075768
PMCPMC8899183
OpenAlexW4207077363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.